Arcion receives U.S. Patent allowance for ARC-2022 to treat PHN Arcion Therapeutics, a clinical stage biotechnology business developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022 kontakter.html read more . With ARC-2022 our objective is to provide lidocaine to your skin without the necessity of an occlusive patch. Campbell, MD, President and CEO of Arcion. We are on the right track to advance ARC-4558 for painful diabetic neuropathy into Phase 3 research and ARC-2022 into further Phase 1/2 research in 2012. ARC-4558 has received fast-track status with the FDA.
7,428,324 entitled ‘System and Way for Data Management in a Linear-array structured Microscope Slide Scanner.’ U.S. Patent 7,428,324 includes several claims for slide scanning systems based on period delay integration arrays, including systems comprising multiple TDI arrays. ‘A TDI array is certainly a two-dimensional array which is usually utilized such as a line-scan video camera,’ stated Dirk Soenksen, CEO of Aperio. ‘We disclosed the TDI approach in detail in several of our early patents, and are very happy to expand our state arranged to encompass this embodiment of line-scanning.’ Related StoriesAnalyzing potential TB vaccineScientists one stage closer to developing brand-new treatment for inflammatory bowel diseaseCombatting viral and bacterial lung attacks with volatile anesthetics: an interview with Dr ChakravarthyThe patent also contains many different statements for managing the large volumes of image data generated from microscope slide scanners, particularly from scanners that utilize line-scan cameras.